차세대 시퀀싱(NGS) 라이브러리 준비 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 시퀀싱 유형별, 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Next-generation Sequencing Library Preparation Market Growth & Trends:

The global next-generation sequencing library preparation market size is anticipated to reach USD 5.33 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 13.3% from 2025 to 2033. Owing the to increasing prevalence of genetic diseases, decreasing costs of sequencing, and rising usage of NGS in disease diagnostics. Moreover, numerous market players offer a broad spectrum of solutions for NGS library preparation to suit the specific requirements of NGS-based analysis.

Advancements in sequencing technology boost the demand for disease panels. NGS libraries are prepared by using nucleotide amplification and sequencing of a specific gene that is causative of a disease condition. The disease diagnosis panels are precisely designed to analyze specific genetic characteristics of a disease condition. For instance, in February 2022, the OncoDNA introduced OncoDEEP kit for analysis of translocations, somatic variants, genomic signatures and predictive biomarkers to aid cancer therapy. The kit also effectively measures tumor mutational burden, microsatellite instability, and loss of heterozygosity.

The COVID-19 pandemic had a significant impact on the adoption of sequencing technology for metagenomics and diagnostics. Furthermore, several key players launched their NGS-based diagnostic tests for COVID-19 and other viral infections. For instance, in April 2021, QIAGEN N.V. released its first-ever QIAseq SARS-CoV-2 diagnostic kit, to be used for the enrichment of the COVID-19 genome and library preparation solution to yield a sequence of the SARS-CoV-2 genome.

Moreover, the growing incidence of diseases and the demand for novel drug discovery, collectively foster the growth of the market. For instance, in September 2022, IDT launches an NGS library preparation solution, xGen monkeypox virus amplicon panel for the precise detection of monkeypox viral infection by genotyping using viral DNA by construction of an NGS library.

Whole-Exome Sequencing is essentially used for the detection of rare genetic disorders by detecting expressive biomarkers that feature mutations, that are causative of various disease conditions. Further, the Whole-Genome Sequencing (WGS) is used for the detection of novel genetic mutations in rare diseases. For instance, in January 2022, researchers at the University of Stanford secured a first-ever Guinness record for a sequencing technique by sequencing a whole human genome in the least turnaround time with a record diagnostic rate for rare disease diagnosis.

Next-generation Sequencing Library Preparation Market Report Highlights:

• By sequencing type, targeted genome sequencing is expected to occupy the larger share in NGS library preparation market due to demand for disease specific analysis of the genome sequence that can cause the disease condition.
• Based on product, the reagents & consumables segment is expected to occupy the bigger share of market space due to the utilitarian benefits that an NGS library preparation kit could offer researchers and clinicians. Ready-to-use NGS library preparation kits require less expertise and bare minimal laboratory infrastructure.
• By application, the drug & biomarker discovery segment dominated the market due to the rise in demand for the discovery of novel drugs and biomarkers for a broad spectrum of disease conditions.
• By end use, Hospital & Clinics segment is expected to grow rapidly over the forecast period owing to the rise in the incidence of cancer, genetic disorders, and other diseases across the globe. The rise in genetic level understanding also positively impacts the growth of this segment.
• North America dominated the global NGS library preparation market in 2024, owing to the rising prevalence of diseases, increasing demand for early diagnosis, the need for genome sequencing, and the presence of key market players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Sequencing Type Segment
  • 1.2.2. Product Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segmental Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. Next-generation Sequencing Library Preparation Market - Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Next-generation Sequencing Library Preparation Market: Sequencing Type Business Analysis

• 4.1. Sequencing Type Segment Dashboard
• 4.2. Global Next-generation Sequencing Library Preparation Market Sequencing Type Movement Analysis, 2024 & 2033
• 4.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Sequencing Type, 2021 to 2033 (USD Million)
• 4.4. Targeted Genome Sequencing
  • 4.4.1. Global Targeted Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Whole Genome Sequencing
  • 4.5.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.6. Whole Exome Sequencing
  • 4.6.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.7. Other Sequencing Types
  • 4.7.1. Global Other Sequencing Types Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Next-generation Sequencing Library Preparation Market: Product Business Analysis

• 5.1. Product Segment Dashboard
• 5.2. Global Next-generation Sequencing Library Preparation Market Product Movement Analysis, 2024 & 2033
• 5.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Reagents & Consumables
  • 5.4.1. Global Reagents & Consumables Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. DNA Library Preparation Kits
    • 5.4.2.1. Global DNA Library Preparation Kits Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. RNA Library Preparation Kits
    • 5.4.3.1. Global RNA Library Preparation Kits Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Other Reagents & Consumables
    • 5.4.4.1. Global Other Reagents & Consumables Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Global Instruments Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Next-generation Sequencing Library Preparation Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Next-generation Sequencing Library Preparation Market Application Movement Analysis, 2024 & 2033
• 6.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Drug & Biomarker Discovery
  • 6.4.1. Global Drug & Biomarker Discovery Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.5. Disease Diagnostics
  • 6.5.1. Global Disease Diagnostics Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Cancer Diagnostics
    • 6.5.2.1. Global Cancer Diagnostics Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Reproductive Health Diagnostics
    • 6.5.3.1. Global Reproductive Health Diagnostics Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Infectious Disease Diagnostics
    • 6.5.4.1. Global Infectious Disease Diagnostics Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Other Disease Diagnostic Applications
    • 6.5.5.1. Global Other Disease Diagnostic Applications Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Global Others Next-generation Sequencing Library Preparation Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Next-generation Sequencing Library Preparation Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Next-generation Sequencing Library Preparation Market End Use Movement Analysis, 2024 & 2033
• 7.3. Global Next-generation Sequencing Library Preparation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals and Clinics
  • 7.4.1. Global Hospitals and Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic and Research Institutions
  • 7.5.1. Global Academic and Research Institutions Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.6. Pharmaceutical and Biotechnology Companies
  • 7.6.1. Global Pharmaceutical and Biotechnology Companies Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Next-generation Sequencing Library Preparation Market: Regional Estimates & Trend Analysis by Sequencing Type, Product, Application, and End Use

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Regulatory framework
    • 8.4.2.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Target disease prevalence
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Regulatory framework
    • 8.4.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Target disease prevalence
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Regulatory framework
    • 8.4.4.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Target disease prevalence
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Regulatory framework
    • 8.5.2.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Target disease prevalence
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Regulatory framework
    • 8.5.3.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Target disease prevalence
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Regulatory framework
    • 8.5.4.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Target disease prevalence
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Regulatory framework
    • 8.5.5.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Target disease prevalence
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Regulatory framework
    • 8.5.6.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Target disease prevalence
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Regulatory framework
    • 8.5.7.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Target disease prevalence
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Regulatory framework
    • 8.5.8.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Target disease prevalence
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Regulatory framework
    • 8.5.9.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Target disease prevalence
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Regulatory framework
    • 8.6.2.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Target disease prevalence
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Regulatory framework
    • 8.6.3.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Target disease prevalence
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Regulatory framework
    • 8.6.4.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Target disease prevalence
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Regulatory framework
    • 8.6.5.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Target disease prevalence
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Regulatory framework
    • 8.6.6.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Target disease prevalence
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Regulatory framework
    • 8.6.7.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Target disease prevalence
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Regulatory framework
    • 8.7.2.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Target disease prevalence
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Regulatory framework
    • 8.7.3.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Target disease prevalence
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Regulatory framework
    • 8.8.2.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Target disease prevalence
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Regulatory framework
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Target disease prevalence
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Regulatory framework
    • 8.8.4.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Target disease prevalence
    • 8.8.5.3. Competitive scenario
    • 8.8.5.4. Regulatory framework
    • 8.8.5.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Agilent Technologies, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. F. Hoffmann-La Roche AG, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. BD
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Oxford Nanopore Technologies
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. New England Biolabs Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Revvity, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. QIAGEN N.V.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Pacific Biosciences of California, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Thermo Fisher Scientific Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives